Background: The majority of current pharmacological treatments for Parkinson's disease
(PD) were approved for clinical use in the second half of the last century and they only …

Since the 1960's treatments for Parkinson's disease (PD) have traditionally been directed to
restore or replace dopamine, with L-Dopa being the gold standard. However, chronic L …

Parkinson's Disease (PD) is the second most common neurodegenerative disorder. Clinical
approaches to manage PD include symptomatic therapies, serving to compensate for the …

Parkinson's disease (PD) is a progressive neurodegenerative disorder that currently has no
cure, but treatments are available to improve PD symptoms and maintain quality of life. In …

Parkinson's disease (PD) is the second most common neurodegenerative disease,
manifesting as a characteristic movement disorder with a number of additional non-motor …

The loss of dopaminergic neurons in the substantia nigra pars compacta leads to the
characteristic motor symptoms of Parkinson's disease: bradykinesia, rigidity and resting …

Parkinson disease is an inexorably progressive neurodegenerative disorder. Multiple
attempts have been made to establish therapies for Parkinson disease which provide …

Many agents developed for neuroprotective treatment of Parkinson disease (PD) have
shown great promise in the laboratory, but none have translated to positive results in …

Parkinson's disease is an increasingly common neurodegenerative condition, which causes
not only dysfunction of movement but also a broad range of nonmotor features, including …

Parkinson's disease (PD) is a neurodegenerative disorder characterized by the
degeneration of dopaminergic neurons and/or loss od neuronal projections, in several …